Last update Aug. 24, 2022
Compatible
We do not have alternatives for Coagulation factor IX, II, VII and X in combination since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Coagulation factor IX, II, VII and X in combination is also known as Prothrombin Complex Concentrate (II, VII, IX & X).
Coagulation factor IX, II, VII and X in combination in other languages or writings:
Coagulation factor IX, II, VII and X in combination belongs to this group or family:
Main tradenames from several countries containing Coagulation factor IX, II, VII and X in combination in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | > 40.000 | daltons |
T½ | 60 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Prothrombin complex concentrates are plasma-derived factor IX preparations that are rich in other coagulation factors: factor II, factor VII, and factor X. They are used in bleeding due to deficiencies of factors II, VII, IX, and X, congenital or by treatment or overdose with vitamin K antagonists (e.g. warfarin) and in the treatment of patients with haemophilia A who have antibodies against factor VIII. intravenous administration.
Since the last update we have not found published data on its excretion in breastmilk.
The very high molecular weight of its different components make it highly unlikely that significant quantities will pass into breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)